Lilly’s Experimental Obesity Drug Shows Promise in Early Study

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the obesity market.

The drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months, according to an abstract posted Friday ahead of the American Diabetes Association conference in Chicago. The drug is moving to the next stage of development and researchers will present details on dosing and safety at the conference next week.

“The data look particularly strong, and should ...